Posted by Michael Wonder on 24 Jul 2020
FDA grants fast track designation for Hanmi LAPS triple agonist
22 July 2020 - Hanmi Pharmaceutical announced on July 16th that its LAPS Triple Agonist (HM15211), an innovative new drug for non-alcoholic steatohepatitis, had received fast track designation from the U.S. FDA.
LAPS triple agonist (Glucagon/GIP/GLP-1) is a first-in-class new drug that can overcome the limitations of single-target oral treatments and utilises Hanmi Pharmaceutical’s proprietary platform technology, LAPSCOVERY.
